• News
  • SAN DIEGO
  • BioTech

Isis begins study for cardiovascular disease treatment

Carlsbad-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) has initiated a Phase 1 clinical study for an anti-sense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
52.75
  1.24  
+ 2.41%
754,830,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
11/03/2014 O Neil, Patrick R 1,500 Sell $69,255
11/03/2014 O Neil, Patrick R 1,500 Sell $69,255
11/03/2014 O Neil, Patrick R 1,500 Exchange $10,875
10/30/2014 Parshall, B Lynne 11,071 Sell $499,535
10/30/2014 Parshall, B Lynne 11,071 Exchange $98,939

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!